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Abstract
Background: Treatment of invasive breast cancer has an alarmingly high rate of failure because effective targets
have not been identified. One potential target is mitochondrial generated reactive oxygen species (ROS) because
ROS production has been associated with changes in substrate metabolism and lower concentration of anti-
oxidant enzymes in tumor and stromal cells and increased metastatic potential.
Methods: Transgenic mice expressing a human catalase gene (mCAT) were crossed with MMTV-PyMT transgenic
mice that develop metastatic breast cancer. All mice (33 mCAT positive and 23 mCAT negative) were terminated at
110 days of age, when tumors were well advanced. Tumors were histologically assessed for invasiveness,
proliferation and metastatic foci in the lungs. ROS levels and activation status of p38 MAPK were determined.
Results: PyMT mice expressing mCAT had a 12.5 per cent incidence of high histological grade primary tumor
invasiveness compared to a 62.5 per cent incidence in PyMT mice without mCAT. The histological grade correlated
with incidence of metastasis with 56 per cent of PyMT mice positive for mCAT showing evidence of pulmonary
metastasis compared to 85.4 per cent of PyMT mice negative for mCAT with pulmonary metastasis (p ≤ 0.05).
PyMT tumor cells expressing mCAT had lower ROS levels and were more resistant to hydrogen peroxide-induced
oxidative stress than wild type tumor cells, suggesting that mCAT has the potential of quenching intracellular ROS
and subsequent invasive behavior. The metastatic tumor burden in PyMT mice expressing mCAT was 0.1 mm
2/cm
2
of lung tissue compared with 1.3 mm
2/cm
2 of lung tissue in PyMT mice expressing the wild type allele (p ≤ 0.01),
indicating that mCAT could play a role in mitigating metastatic tumor progression at a distant organ site.
Expression of mCAT in the lungs increased resistance to hydrogen peroxide-induced oxidative stress that was
associated with decreased activation of p38MAPK suggesting ROS signaling is dependent on p38MAPK for at least
some of its downstream effects.
Conclusion: Targeting catalase within mitochondria of tumor cells and tumor stromal cells suppresses ROS-driven
tumor progression and metastasis. Therefore, increasing the antioxidant capacity of the mitochondrial
compartment could be a rational therapeutic approach for invasive breast cancer.
Please see related commentary article: http://www.biomedcentral.com/1741-7015/9/62
Background
The chance of developing invasive breast cancer during
aw o m a n ’s lifetime is approximately 1 in 8 and more
than 40,000 American women die of metastatic disease
each year [1]. Despite making significant progress in elu-
cidating the molecular mechanisms for breast cancer
initiation and progression, effective treatments against
metastatic progression remain elusive. Treatment of
metastatic disease has an alarmingly high rate of failure
because effective targets have not been identified. Inher-
ent or acquired tumor drug resistance and dose-limiting
toxicity limit many agents used in the treatment of
breast cancer. This is observed through the lack of suc-
cess in conventional chemotherapeutic trials, as well as
the inability to prevent metastatic growth by surgical
resection of the primary tumor.
It has recently been reported that mitochondrial poly-
morphisms associated with alterations in mitochondrial
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any medium, provided the original work is properly cited.function play a role in women’s risk for invasive breast
cancer [2] suggesting a role for reactive oxygen species
(ROS) production. In transformed epithelial cells, consti-
tutively activated mitogenic pathways increase intracellu-
lar ROS, and activated metabolic pathways further
increase the levels of endogenous ROS [3]. A decline in
mitochondrial energy production can generate increased
ROS, which cause mitochondrial mutations and addi-
tional ROS production [4,5]. As a consequence of mito-
chondrial dysfunction, cells are chronically subjected to a
pro-oxidative environment [6], that is associated with
tumor invasiveness [7], changes in tumor substrate meta-
bolism [8], a lower concentration of anti-oxidant
enzymes in tumor cells [9,10], and increased production
or reduced clearance of ROS [11]. The molecular
mechanisms of ROS-driven tumor progression are not
well understood, but it is important to consider that sub-
lethal concentrations of ROS are second messengers that
up-regulate the expression of pathways involved in
tumor growth and metastasis, such as p38MAPK [12].
Lethal concentrations of ROS may have the opposite
effect and trigger cell death pathways for tumor cells [13].
ROS-driven pathways likely function in stromal cells as
well as tumor cells. Recent work has shown that cancer
associated fibroblasts undergo tumor mediated oxidative
stress, which can then drive metabolic and mutagenic
activities of tumor cells [14]. The suggestion is that stromal
fibroblasts undergo aerobic glycolysis to generate energy-
rich metabolites such as lactate and pyruvate, which are
directly used by tumor cells to support oxidative phosphor-
ylation. The resultant oxidative stress is significant to pro-
mote genomic instability in adjacent cancer cells,
indicating that the tumor stroma can potentially increase
cancer cell aggressive behavior via a bystander effect.
There is evidence to suggest that mitochondrial-gener-
ated oxidative stress can be attenuated with clinically
relevant health benefits by increasing the concentration
of mitochondrial antioxidant enzymes [15], or by ectopi-
cally expressing antioxidant enzymes within mitochon-
dria [16,17]. Strategies to target cofactor-independent
antioxidants, such as catalase, within the mitochondrial
membrane would be predicted to effectively eliminate
H2O2 at its source and prevent the formation of hydro-
xyl radicals and the subsequent cellular damage that can
lead to a protumor environment. We report in this
paper that transgenic expression of mitochondrial tar-
geted catalase in a clinically relevant mouse model of
invasive breast cancer decreases primary tumor invasive-
ness and metastatic tumor severity.
Materials and methods
Animals
FVB/N-Tg (MMTV-PyMT) 634 Mul/J transgenic males
on a 100% FVB background [18] were obtained from
Jackson Labs and crossed with mitochondrial targeted
(mCAT) transgenic females on a congenic C57/BL6
background [17]. PyMT is a membrane bound polypep-
tide that can be regarded as an active analogue of a
receptor that harbors docking sites for a number of
effecter proteins used by tyrosine kinase receptors to sti-
mulate mitogenesis. In fact, the same signaling pathways
are activated as for ErbB2, an oncogene amplified or
overexpressed in approximately 30 per cent of human
breast cancers [19]. Mammary gland specific overexpres-
sion of PyMT using the MMTV promoter results in
multifocal mammary adenocarcinomas with relatively
short median latency and nearly 100 per cent metastasis
to lungs and less frequently to lymph nodes [18]. The
model shares numerous characteristics with human
breast tumors. First, tumors develop with high pene-
trance and show gradual loss of estrogen and progester-
one receptors. Second, the full multistage progression
from hyperplasia to full-blown malignancy and metasta-
sis is represented. Third, metastatic potential appears to
be independent of hormonal fluctuations with a repro-
ducible and measurable progression rate. A recent
report has shown that PyMT transgenic mice on the
C57BL/6 background have a longer mammary tumor
latency (92 days) compared to PyMT on the FVB back-
ground (53 days) [20]. The incidence of lung metastasis
is only slightly reduced. Our own data show that PyMT
mice on the FVB background crossed with wild type
C57BL/6 mice have a consistent and reproducible tumor
latency time period of 70 days and still maintain a high
incidence of lung metastasis (unpublished observations).
Therefore, PyMT × mCAT F1 mice represent a useful
and relevant model to study the effect of mCAT on
tumor progression. Animals were kept in ventilated
cages (4 to 5 per cage) in a specific pathogen free facility
at the University of Washington. Mice were fed standard
chow and provided reverse osmosis water. All supplies
entering the facility were autoclaved. Rooms were kept
at a 12-hour light/dark cycle, maintained at 70-74°F, 45-
55% humidity with 28 changes per hour. Sentinel mice
were tested every quarter and were negative for standard
mouse pathogens.
Experimental F1 cohorts included PyMT × mCAT F1
transgenic (N = 18), PyMT transgenic × mCAT wild
type (WT) (N = 12), PyMT WT × mCAT WT (N = 9),
and PyMT WT × mCAT transgenic (N = 13) mice. The
experimental procedure was repeated and included
PyMT × mCAT (N = 15) and PyMT × WT (N = 11) lit-
termates. Mice were palpated weekly for mammary
tumors beginning at 60 days of age. Primary tumor inci-
dence was determined by the presence of palpable mam-
mary tumors for each genotype. Mice were sacrificed at
110 days of age by carbon dioxide asphyxiation, followed
by necropsy. Standard necropsy procedures were
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weighed and fixed with 10% neutral buffered formalin.
Primary tumor volumes were determined by measuring
in 3 dimensions with digital calipers and calculated as
the product of length, width and height. Tissue samples
were transferred into 70% ethanol after 24 hours. Fixed
tissues were then paraffin embedded and 5 μMs e c t i o n s
obtained for hematoxylin and eosin (H&E) staining. All
experiments were approved by the University of
Washington Institutional Animal Care and Use
Committee.
Primary cell cultures
Mammary tumors were aseptically excised from the
fourth mammary fat pad from PyMT mice positive or
negative for mCAT. Tumor explants were then washed
with PBS and serum-free DMEM, placed in sterile petri
dishes and mechanically dissociated and transferred to
separate sterile petri dishes and DMEM with 20%FBS
and 1% penicillin/streptomycin (Gibco/BRL Life Tech,
Carlsbad, CA). Cells were then placed in an incubator at
37°C and 5% CO2. Media was replaced every 2-3 days
until cells were near confluence. After confluence, cells
were trypsinized and passaged onto multiple petri dishes
and fed DMEM with 10% FBS and 1% penicillin/strepto-
mycin. Once cells from the first passage became conflu-
ent, they were trypsinzed, passaged and frozen with
freezing medium (DMEM with 20% FBS and 10%
DMSO) and stored in liquid nitrogen. Lungs were har-
vested and treated in the same manner as the mammary
tumors.
Pathological assessment
H&E stained tumor tissues were assessed for morphol-
ogy and general appearance, including: i) number of
adenoma and carcinoma per tissue, ii) scirrhous
response (scored from 0 to 4), iii) necrosis (scored from
0 to 4), iv) squamous metaplasia (scored from 0 to 2), v)
inflammation (scored from 0 to 3), vi) degree of anapla-
sia (scored as either 0 or 1) and vii) invasion (scored
from 0 to 3). Invasive foci were characterized by neo-
plastic acini or single cells present in the surrounding
tissues including the mammary fat pad adipose tissue
and deep underlying striated musculature. Invasion
scores were applied with increasing severity as grade 1,
a small single focus less than 20 cells or 1 acini; grade 2,
multiple small foci consisting of single cells or small sin-
g l ea c i n i ;a n dg r a d e3 ,m u l t i p l ei n v a s i v ea c i n iw i t h i n
multiple foci. Pulmonary metastatic foci and tumor bur-
den were quantified from paraffin-embedded, H&E
stained lung tissue sections. Slides were scanned to vir-
tual digital files using Nanozoomer (Hamamatsu, Hama-
matsu City, Japan). Images were magnified to 2.5× and
were captured and used for quantification. The number
of metastatic foci was counted in the entire 2.5× image.
Metastatic incidence was defined as the number of mice
bearing metastatic foci relative to the number of mice
that did not have any metastatic foci. For metastatic
tumor burden quantification, the ratio of tumor area to
total lung surface area (square mm of pulmonary meta-
static foci/square cm of lung tissue) was quantified
using the Nikon Basic Research Image analysis software
package.
Ki-67 immunohistochemistry
Ki-67 is a cancer antigen that is found in rapidly growing,
dividing cells but is absent in the rest phase of cell growth.
To identify cells expressing ki-67, formalin-fixed mam-
mary gland sections were immunostained using rabbit
polyclonal to ki-67 proliferation marker (Abcam, Cam-
bridge, MA Cat No. ab15580, Lot No. 465068, 0.5 mg/mL)
in an automated immunstainer. Slides were deparaffinized
for 30 minutes at 60°C. Antigen retrieval was achieved by
adding Bond HIER 2 (EDTA) for 20 minutes, at 100°C.
Endogeneous peroxidase activity was blocked using Leica
Bond Peroxide block, 5 minutes at RT. To eliminate non-
specific interactions of secondary antibodies, tissues were
incubated with 10% normal serum from the same host
that had been used to generate the secondary antibodies.
Sections were incubated for 20 minutes using diluted nor-
mal blocking serum, serum excess removed and primary
antibody, Rabbit Ki-67 1:2000 (0.25 mg/mL), or Rabbit iso-
type 1:5000 (0.2 mg/mL) as negative control, were added
to the slides after diluted in Leica primary antibody diluent
for 15 min at RT. Specific reactivity was detected using
Leica Bond Polymer DAB Refine, 8 minutes at RT and
Leica Bond Mixed Refine (DAB) detection 10 minutes at
RT. Tissues were counterstained for 10 seconds in Harris
Hematoxylin followed by two rinses in H2O and cleared
with Xylene. Slides were mounted with a cover slip. The
number of ki-67 labeled cells was determined by counting
positive cells in a grid of eight squares encompassing the
entire plane of view at 200× magnification per slide. The
ki-67 labeling index was calculated as the average per cent
positive cells.
Catalase assay
Cells were grown to confluence in DMEM supplemen-
ted with 10% FBS and placed in a two-chambered slide
system. Cells were then washed with PBS, and fixed
with 4% paraformaldehyde, permeabilized for 30 min-
utes with TBST (50 mM Tris-Hcl, pH 8.0, 140 mM
Nacl, 2.7 mM KCl, 0.1% Triton-X100 and 0.3% BSA) at
room temperature, and stained with primary anti-
human catalase (sc43282, Santa Cruz), followed by
Alexa-488 (Invitrogen) secondary antibodies, and coun-
terstained with Hoechst 33342. Images were obtained
using a Zeiss-confocal microscope.
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Cells were grown to confluence in DMEM supplemen-
ted with 10% FBS, at 37°C and 5% CO2. Confluent cells
were passaged and a cell-count was performed. 10,000
cells were seeded per well in a 96-well plate. Cells were
then incubated for 4 hours at 37°C and 5% CO2,t o
allow adhesion. Cells were then probed for ROS using a
DCFH-DA-based, intracellular ROS assay (STA-342;
Cell Biolabs, CA), as per manufacturer’s instructions. In
brief, media was removed and cells were washed twice
with PBS (14190-250; Gibco/BRL Life Tech, Carlsbad,
CA). 100 μl of the cell-permeable, fluorogenic probe 2’-
7’-dichlorodihydrofluorescein diacetate (DCFH-DA),
diluted in serum-free DMEM, was added to each well
and cells were incubated for 30 minutes. Wells were
washed again, thrice, with PBS, at which point the cells
were lysed and fluorescence was quantified with a
microplate reader (Perkin Elmer Victor3 V multi-mode)
set at 485 nm (excitation) and 535 nm (emission). A
corresponding plate, also seeded at 10,000 cells per well
and pre-incubated for 4 hours under the same condi-
tions, was assayed for rate of mitochondrial electron
transport using the tetrazolium salt WST-1 as per man-
ufacture instructions (1-644-807; Roche, Mannheim,
Germany). In brief, cells were incubated for 1.5 h in 100
μlo fs e r u m - f r e eD M E Mw i t h1 0μlo fW S T - 1r e a g e n t ,
and then absorbance at 450 nm, which is directly related
t ot h er a t eo fa c t i v i t yo fm i t o c h o n d r i a ld e h y r o g e n a s e ,
was read using a microplate reader. The amount of ROS
in each well was standardized to the rate of mitochon-
drial electron transport, and the probability of significant
difference was calculated using a Student’s t-test.
Cell viability
C e l l sw e r ep l a t e di nD M E Mw i t h1 0 %F B Sa n d1 %P e n -
Strep (Gibco/BRL Life Tech, Carlsbad, CA) in 96-well
plates. After 24 hours, media was removed, and cells
w e r et r e a t e dw i t h0 ,0 . 5 ,0 . 7 ,0 . 8 5 ,1 . 0a n d2 . 0m MH 202
(H324-500; Fisher Scientific, Auburn, WA), in DMEM/
10% FBS/1% Pen-Strep. After being incubated with their
respective treatments for 4 h at 37°C in a humidified
atmosphere with 5% CO2, all wells were replaced with
100 μl of fresh media/10% FBS/1% Pen-Strep. Cells were
allowed to recover for another 48 h at 37°C in a humidi-
fied atmosphere with 5% CO2.1 0μl of Cell Proliferation
Reagent WST-1 (BD Biosciences, Mountain View, CA)
was added to each well and cells were put back in the
incubator for another 1.5 hours. Plates were then shaken
thoroughly on a shaker, and the absorbance of each of
the wells was measured using a microplate reader at 450
nm. Wells without cells were used as a blank, and aver-
age absorbances for each H2O2 treatment were standar-
dized relative to the absorbance at 0 mM H2O2.
Viability was recorded as per cent viable cells.
Western immunoblotting
Cells were treated with 0, 100 and 500 μMH 2O2 (H324-
500; Fisher Scientific, Auburn, WA) for 4 hours. They
were then washed with PBS (14190-250; Gibco/BRL Life
Tech, Carlsbad, CA), trypsinized for 5 to 10 min at 37°
C, and pelleted. Cells of each plate were resuspended in
200 μl RIPA buffer (89901; Thermo Scientific) with 10
μl each of protease and phosphatase inhibitors P8340,
P2850 and P5726 (Sigma-Aldrich) and then sonicated to
extract total cytosolic protein. Westerns were run with
20 ug protein per lane. Primary antibodies were used to
target the following: Phospho-p38MAPK (Thr180/
Try182) and p38MAPK (#9211 and #9212; Cell Signal-
ing Technology). Primary antibodies were then labeled
with an HRP-conjugated secondary antibody (ab6721;
Abcam). HRP was detected by using an ECL Western
Blotting Analysis System (RPN2109; Amersham Bios-
ciences). A densitometric analysis was done to quanti-
tate individual intensities of the bands.
Statistical analysis
Differences in the proportions of primary and metastatic
tumor incidence as well as proportion of high-grade pri-
mary lesions between PyMT expressing mCAT and
PyMT negative for mCAT were evaluated using a 2 × 2
contingency table. A Fisher’s exact test was used to test
for statistical differences, with significance set at p ≤ 0.05.
Differences in mean tumor volumes, tumor weights/bur-
den, as well as relative fluorescent units and relative
absorbance between the two genotypes were carried out
using student’s t-test with significance set at p ≤ 0.05.
Results
Mitochondrial catalase decreases invasiveness of primary
breast tumors
The presence of mitochondrial catalase (Figure 1) had a
profound affect on the invasive phenotype of the primary
tumor, with an average invasive grade of 1.8 ± 0.5 while the
average invasive grade of tumors in the absence of mCAT
was 2.8 ± 0.5, p ≤ 0.03 (Table 1). Only 13 per cent of
tumors with mCAT displayed a histologically invasive phe-
notype of grade 3, while 63 per cent of tumors without
mCAT had a histologically invasive grade of 3. Invasiveness
was represented by glandular infiltration into surrounding
skeletal muscle fibers (Figure 2A). In contrast, a greater
number of mammary tumors from PyMT mice positive for
mCAT showed features of well-encapsulated adenoma with
peritumoral inflammation (Figure 2B). The difference of
high-grade invasiveness in primary tumors was reflected in
ki-67 labeling with 56 per cent positive in PyMT cells (Fig-
ure 2C) compared to 21 per cent positive in PyMT cells
expressing mCAT, p ≤ 0.05 (Figure 2D). The difference in
high-grade invasiveness in primary tumors was also
reflected in metastatic tumor incidence to the lungs.
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mice expressing the wild type mCAT allele, while only 56
per cent of PyMT mice expressing mCAT showed pulmon-
ary metastasis (P ≤ 0.05) (Table 1). Although the histologi-
cal phenotype of the primary tumors was drastically
different between PyMT mice positive or negative for
mCAT, primary tumor burden was not statistically different
(Table 1), suggesting that mCAT may be reducing stromal
infiltration and cellular motility and migration of primary
tumors, either through direct effects on the tumors them-
selves, or via some cross-talk with stromal cells.
Primary tumor cells from mCAT Tg mice are resistant to
oxidative stress
In order to provide preliminary insight into the role of
ROS signaling in the invasive phenotype, we determined
whether mammary tumor cells expressing mCAT were
more resistant to oxidative stress than mammary tumor
cells from WT littermates, and looked to see if they had
lower intracellular concentrations of ROS. PyMT mam-
mary tumor cells positive for mCAT showed reduced
ROS concentrations compared with PyMT tumor cells
negative for mCAT (Figure 3A), and were more resistant
to the toxic affects of increasing concentrations of H2O2
(Figure 3B). Therefore, the presence of mCAT in PyMT
cells appears to quench intracellular ROS making them
less sensitive to the invasive promoting effects of ROS,
and suggesting that targeting mitochondria within pri-
mary tumor cells with catalase is a potentially relevant
clinical strategy to prevent, or at least slow the rate, of
invasive breast cancer progression.
Metastatic tumor burden is decreased in the presence of
mCAT
PyMT mice positive for mCAT showed a more than two-
fold decrease in the average number of metastatic foci in
A B C
D E F
Figure 1 Catalase is targeted to mitochondria of tumor cells from mCAT positive PyMT mice. Mammary tumor cells stained with human
primary anti-catalase and Alexa 488 secondary antibodies and counter-stained with Hoechst 33342 staining for the nucleus. A-C showing
nuclear stain, mitochondrial catalase stain and overlap in PyMT cells expressing mCAT and D-F in PyMT cells negative for mCAT, respectively.
Table 1 Breast tumor invasiveness in polyoma middle T (PyMT) transgenic mice positive or negative for mitochondrial
targeted catalase (mCAT)
PyMT Genotype Number of
mice
Primary tumor
incidence
Average Invasion
Grade
Metastatic tumor
incidence
Metastatic tumor
burden
a
WT 23 100% 2.8 ± 0.5 85.4% 1.3 ± 0.3
mCAT 32 97% 1.8 ± 0.5*
b 56.0%** 0.1 ± 0.02***
a) Metastatic tumor burden expressed as mm
2 tumor/cm
2 lung. b) Significant at P ≤ 0.03*; P ≤ 0.05**, or P ≤ 0.01***.
Mice were from two separate experiments that were each terminated at 110 days of age.
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tumor burden, compared with mCAT negative PyMT lit-
termates (0.1 square mm per square cm of lung tissue ver-
sus 1.3 square mm per square cm of lung tissue,
respectively, P ≤ 0.01) (Table 1). Figure 4 shows a repre-
s e n t a t i v es c a n n e dH & Es t a i n e ds l i d eo fl u n g sf r o ma n
mCAT negative (4A) or mCAT positive (4B) PyMT
mouse, where larger metastatic tumor foci are seen in the
absence of mCAT compared to much smaller foci in the
presence of mCAT. The difference was reflected in ki-67
labeling with 23 per cent positive in PyMT cells (Figure
4C) compared to 6 per cent positive in PyMT cells expres-
sing mCAT, p ≤ 0.01 (Figure 4D). Therefore, mCAT
appears to play a role in suppressing progression and pro-
liferation of tumor foci at a distant site of metastasis.
Expression of mCAT in the lungs increases ROS resistance
We asked the question whether pulmonary stromal cells
that expressed mCAT displayed any resistance to
oxidative stress. Lung fibroblasts were obtained from
mice that were either wild-type or transgenic for
mCAT. ROS levels were decreased in lung fibroblasts
from mCAT positive mice compared to wt mice (Figure
5A). When treated with H2O2 and their viability com-
pared, lung fibroblasts that expressed mCAT were more
resistant to H2O2 than wild-type lung fibroblasts and
displayed greater viability at the same concentration of
H2O2 (Figure 5B), suggesting that mCAT is capable of
neutralizing the effect of ROS in cells in the pulmonary
microenvironment.
ROS are associated with activation of p38MAPK
One of the molecular mechanisms helping mediate the
ROS resistant process may be the p38MAPK pathway
[12]. We show that increasing levels of ROS are asso-
ciated with increases in phosphorylation of p38MAPK,
but this phosphorylation is dramatically attenuated in
t h ep r e s e n c eo fm C A T( F i g u r e6 A ) ,s u g g e s t i n gt h a t
A                                                                        B 
CD
Figure 2 Histological sections of mammary tumors stained with H and E or ki-67 antibody. A. Invasion was identified based on growth
patterns such as glandular infiltration into surrounding skeletal muscle fibers (arrow) in tumors from PyMT mice negative for mCAT. Invasive foci
were scored from 0 (none) to 3 (multiple invasive fronts). B. Low grade, encapsulated adenomas (closed arrow head) were more common in
PyMT mice expressing mCAT. C. Ki-67 staining of PyMT primary tumor cells negative for mCAT showed a labeling percent of 56. D. Ki-67 staining
of PyMT primary tumor cells positive for mCAT showed a labeling percent of 21. The difference in ki-67 labeling between mCAT positive and
mCAT negative PyMT primary tumor cells was significant at p ≤ 0.05.
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pathway.
Discussion
Our results show that PyMT transgenic mice expressing
mCAT have reduced primary tumor invasiveness and
decreased pulmonary metastatic tumor incidence and
burden, compared with PyMT mice expressing the WT
allele. These findings are in agreement with our pre-
viously reported observations that old transgenic mice
expressing mCAT had less invasive epithelial cancers,
compared with wild type littermates [17]. A possible
explanation for the protective effect of mCAT in the
PyMT model system could be due to an abrogation of
ROS-dependent signaling required for attaining invasive
behavior. Our data show that PyMT mammary tumors
expressing mCAT are mainly comprised of well-
encapsulated adenomas (Figure 2B), whereas PyMT
mammary tumors negative for mCAT had increased
invasion represented by glandular infiltration into skele-
tal muscle (Figure 2A). It is possible that mCAT alters
ROS-dependent signaling involved in epithelial-to-
mesenchymal transition (EMT), a process associated
with metastasis. Hypoxia, which is common in tumors
[21], stimulates the production of mitochondrial gener-
ated ROS [22], which can promote EMT and metastasis
through activation of a number of different factors [23].
Increases in ROS that have no effect on normal cells
can actually promote cancer cell growth [24,25], and we
have shown that mCAT confers resistance of PyMT
cells to increasing levels of H2O2.H y p o x i ai np e r i -
necrotic areas surrounding a tumor may release vascular
endothelial factors, which act as powerful chemoattrac-
tants for tumor-associated macrophages (TAMs) in
A
B
Figure 3 Tumor cells expressing mCAT are resistant to oxidative stress. A. Primary PyMT tumor cells expressing mCAT have lower levels of
ROS compared to tumors cells from wild type littermates. p ≤ 0.05. B. PyMT mammary tumors expressing mCAT are resistant to H2O2
compared to PyMT mammary tumors negative for mCAT, *p < 0.05, **p < 0.001.
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port tumor progression [27] by promoting invasion,
angiogenesis and metastasis [28] as a consequence of
tissue hypoxia and the subsequent generation of ROS. It
has also been reported that endothelial cells and fibro-
blasts along with TAMs up-regulate monocyte chemoat-
tractant protein (MCP)-1 [29]. Thus, a complex cross-
talk between ROS, stromal cells and tumor cells occurs
to promote invasive behavior.
An additional explanation for the protective effect of
mCAT in the PyMT model system is based on the con-
cept that high levels of ROS produced by cancer cells
increase their motility by degrading the surrounding
extracellular matrix, leading to increased potential for
migration and invasion. It is believed that metastasis fol-
lowing surgical removal of tumors is in part due to ROS
generated by the procedure, an idea that is supported by
the fact that superoxide dismutase (SOD) derivatives
inhibit the growth of micrometastasis after surgical
removal of tumors in mice [30]. Mitochondrial DNA
(mtDNA) is also known to play a role in the metastatic
behaviour of tumor cells. If mtDNA in a poorly meta-
static tumor cell line is replaced with mtDNA from a
highly metastatic cell line and vice versa, recipient
tumor cells acquire the metastatic potential of the
mtDNA donor. Mutations in mtDNA occur at high fre-
quency in tumor cells, and those that cause overproduc-
tion of ROS are associated with increased metastatic
potential. Pretreatment of these cells with ROS scaven-
gers can decrease their ability to metastasize [31]. ROS
generated by H2O2 at sub-lethal concentrations can act
as an intracellular second messenger to increase
A                                                           B


      C                                                    D 
Figure 4 Metastatic tumor burden and proliferative capacity are decreased in the presence of mCAT. Surface area of metastatic foci in
lungs of PyMT/WT mice (A) was significantly larger than metastatic foci in lungs of PyMT/mCAT mice (B). Arrows indicate metastatic tumors.
Original magnification was at 2.5×. C. Ki-67 staining of PyMT metastatic tumor cells negative for mCAT showed a labeling percent of 23. D. Ki-67
staining of PyMT metastatic tumor cells positive for mCAT showed a labeling per cent of 6. The difference in ki-67 labeling between mCAT
positive and mCAT negative PyMT metastatic tumor cells was significant at p ≤ 0.01.
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of tumor cells in metastatic colonies [32]. Finally, dis-
rupting the mitochondrial respiratory chain leads to
increased ROS and has been shown to increase the
motility and invasiveness of breast cancer cells through
mechanisms mediated by cytokines such as CXCL14 [6].
Other mechanisms may also be involved in the protec-
tive affect of mCAT. A recent study showed that cyto-
keratin positive tumor cells were found in bone marrow
of PyMT mice as early as 4 to 6 weeks of age, coincid-
ing with atypical ductal hyperplasia (ADH) and ductal
carcinoma in situ (DCIS) in mammary tissue [33]. This
suggests that disseminated tumor cells from the mam-
mary tissue may be present at distant organs at an early
stage of tumor progression and remain dormant. The
fact that reduced metastatic foci were observed in
PyMT lungs positive for mCAT suggests that mCAT
could be either reducing primary tumor dissemination
at an early stage of tumorigenesis, or attenuating growth
signals at the secondary site, or both. A putative
mechanism for this could involve the cellular stress sen-
sor p38MAPK, where its expression is positively corre-
lated with invasive breast cancers [34], as well as EMT
and cell migration [35]. Our immunoblots show that in
mCAT transgenic lung fibroblasts, p38MAPK was phos-
phorylated at a higher concentration of H2O2, compared
with wild-type lung fibroblasts, where p38MAPK was
phosphorylated at a 5-fold lower concentration. Our
        A 
     B 
Figure 5 Resistance to ROS is increased in lung fibroblasts expressing mCAT. A) Lung fibroblast cells expressing mCAT have lower levels of
ROS compared to lung fibroblast cells from wild type littermates, p ≤ 0.05, and B) are more resistant to H2O2 challenge, ***p < 0.001.
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mCAT would have a lower expression of p38MAPK,
which could be attributed to decreased cellular stress,
presumably in this context, lower oxidative stress. A
reduced expression of p38MAPK in the lung fibroblasts
may translate to lower E- and P-selectin expression,
thus attenuating the metastatic potential of tumor cells
by weaker attachment and seeding at the target organ
[36]. Increased anti-oxidative capacity of surrounding
stromal cells in the PyMT lungs positive for mCAT may
thus alter their molecular cross-talk with metastatic
tumor cells and hence inhibit their colonization [37].
Recent data have suggested an association with ROS
levels in tumor epithelial cells and stromal fibroblasts
[14]. Signals from tumor epithelial cells initiated meta-
bolic dysfunction resulting in increased ROS that
directly affected tumor cells by enhancing their invasive
and metastatic qualities. That increased levels of ROS
enhance tumorigenesis may seem a paradox in view of
recent findings that increased ROS can also be
associated with increased apoptosis of tumor cells and
decreased tumor proliferation [13]. However, it may be
that it is a matter of ROS concentration, ie., high con-
centrations of ROS generated in overwhelming and
severe mitochondrial damage trigger tumor cell apopto-
sis as a feature of overzealous tumor cells. On the other
hand, tumor cells that have adapted more to a con-
trolled environment are able to use ROS to their advan-
tage by inducing stromal fibroblasts, as well as other
stromal cells, as mediators of survival.
Conclusions
Our findings describe how transgenic expression of
mCAT in PyMT mammary cancer decreases primary
tumor invasiveness and suppresses pulmonary metas-
tases. From a clinical perspective, mitochondrial targeted
catalase should be considered as a potential adjuvant
treatment strategy for further investigation to help pre-
vent metastasis in women diagnosed with invasive breast
cancer.
      A 
     B 
A
v
e
r
a
g
e
 
b
a
n
d
 
p
i
x
e
l
 
d
e
n
s
i
t
y
 
Figure 6 Phosphorylation of p38MAPK is decreased in the presence of mCAT. A. Immunoblot of total protein extract from MCAT (Tg/+)
and WT (+/+) primary tumor cells. B. Immunoblot of total protein extract from MCAT (Tg/+) and WT (+/+) lung fibroblasts, treated for 4 hours
with 0, 100 and 500 μMH2. Lung fibroblast cells expressing mCAT attenuate phosphorylation of p38MAP kinase in the presence of increased
levels of oxidative stress. ***p < 0.0001.
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